A student discovered connection, access and belonging as he navigated the Everglades and other natural and manmade wonders ...

Baylor College of Medicine’s board of trustees named Dr. Jakub Tolar the next president, CEO and executive dean of the ...

The Class 12 Biology practical examination plays a crucial role in the board results, and the viva voce (oral exam) often ...

MONTREAL, /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1 ...

U.S. Patent No. 12,329,781 relates to Minovia’s proprietary mitochondrial augmentation technology for the treatment of renal diseases, including renal tubulopathy, kidney insufficiency, and chronic ...

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to ...

WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...

Researchers from Tokyo Metropolitan University have developed a suite of algorithms to automate the counting of sister ...

New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 followin ...

In other news, on December 30, Ultragenyx Pharmaceutical completed its rolling BLA submission to the FDA for DTX401, which is ...